MGMT and glioblastoma: Therefore, careful reconsideration whether lomustine treatment is of sufficient added benefit for patients with a glioblastoma is warranted when taking into consideration current guidelines such as the ESMO-Magnitude of Clinical Benefit Scale and the ASCO Value Framework Net Health Benefit Score.51-53 Potential biomarkers, such as MGMT status, might play a role in patient selection for treatment with lomustine but need formal proof.